Bridget Rund, NP
Nurse Practitioner · Bloomington, INNPI 1528376779
Payments from drug & device makers
Across 361 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$864
- AbbVie$784
- Alkermes, Inc.$684
- Neurocrine Biosciences, Inc.$580
- Otsuka America Pharmaceutical, Inc.$497
- Lundbeck LLC$390
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,098100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 57 | $864 |
| AbbVie | 52 | $784 |
| Alkermes, Inc. | 38 | $684 |
| Neurocrine Biosciences, Inc. | 34 | $580 |
| Otsuka America Pharmaceutical, Inc. | 27 | $497 |
| Lundbeck LLC | 27 | $390 |
| Vanda Pharmaceuticals Inc. | 14 | $371 |
| Johnson & Johnson | 16 | $294 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $204 |
| E.r. Squibb & Sons, L.L.C. | 16 | $200 |
| Axsome Therapeutics, Inc. | 8 | $171 |
| Gilead | 6 | $128 |
| Noven Therapeutics, LLC | 6 | $111 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Indivior Inc. | 4 | $71 |
| AstraZeneca | 2 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| Supernus Pharmaceuticals, Inc. | 4 | $67 |
| Exact Sciences | 3 | $54 |
| Pfizer | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 3 | $47 |
| Verona Pharma, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $33 |
| Viiv Healthcare Company | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $29 |
| GSK | 2 | $24 |
| Abbott | 1 | $23 |
| Tris Pharma Inc | 1 | $21 |
| Corium, LLC | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Ardelyx, Inc. | 1 | $13 |
How this compares
$6,098 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 36 | $56,366 |
| JardianceEmpagliflozin | 92 | $55,198 |
| MounjaroTirzepatide | 47 | $52,268 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $50,173 |
| Invega SustennaPaliperidone Palmitate | 13 | $46,564 |
| TrulicityDulaglutide | 28 | $31,775 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 60 | $29,266 |
| JanuviaSitagliptin Phosphate | 43 | $23,905 |
| VraylarCariprazine Hcl | 13 | $19,435 |
| OzempicSemaglutide | 13 | $15,267 |
| TrintellixVortioxetine Hydrobromide | 20 | $9,573 |
| EliquisApixaban | 14 | $8,474 |
| MyrbetriqMirabegron | 15 | $7,556 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,492 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $24 | $86,855148 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $497 | $56,36636 claims |
| Johnson & JohnsonInvega Sustenna | $294 | $46,56413 claims |
| AbbVieVraylar, Linzess | $784 | $26,69826 claims |
| Novo NordiskOzempic | $16 | $15,26713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $68 | $9,57320 claims |
| PfizerEliquis | $53 | $8,47414 claims |
| Astellas Pharma US IncMyrbetriq | $33 | $7,55615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Bloomington
- Theresa WoodardBloomington$14K
- Veneda VannBloomington$9K
- Kristi OrbaughIndianapolis$1.3M
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
- Kacy RogersIndianapolis$77K
- Kristine TaylorFort Wayne$69K
- Brittany SavageIndianapolis$51K
- Monica HaugerTrafalgar$47K
- Rhonda HettingerClarksville$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.